Virginia Ammendola

Rome, 00128, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Efficacy, pharmacokinetics, and safety in the mouse and primate retina of dual AAV vectors for Usher syndrome type 1B.

Efficacy, pharmacokinetics, and safety in the mouse and primate retina of dual AAV vectors for Usher syndrome type 1B.

Journal: Molecular therapy. Methods & clinical development

Published: November 09, 2022

GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults.

GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults.

Journal: Science translational medicine

Published: October 26, 2021

Correction: A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C.

Correction: A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C.

Journal: PLoS neglected tropical diseases

Published: April 13, 2021

MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans.

MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans.

Journal: Science translational medicine

Published: October 08, 2019

A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C.

A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C.

Journal: PLoS neglected tropical diseases

Published: September 27, 2019

CRISPR/Cas9-Mediated In Situ Correction of LAMB3 Gene in Keratinocytes Derived from a Junctional Epidermolysis Bullosa Patient.

CRISPR/Cas9-Mediated In Situ Correction of LAMB3 Gene in Keratinocytes Derived from a Junctional Epidermolysis Bullosa Patient.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: February 05, 2018

Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection.

Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection.

Journal: Vaccines

Published: June 07, 2016

Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans.

Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans.

Journal: Hepatology (Baltimore, Md.)

Published: July 22, 2015

Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates.

Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates.

Journal: Molecular therapy. Methods & clinical development

Published: February 17, 2015

A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory.

A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory.

Journal: Science translational medicine

Published: November 08, 2014

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge.

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge.

Journal: Nature medicine

Published: August 18, 2014

Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.

Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.

Journal: Journal of virology

Published: March 07, 2014

Showing 1-12 of 17

Last Updated: 09/26/2026